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The Plasmodium vivax reticulocyte-binding protein (RBP) family was identified based on the 
annotation of adhesive ligands in the P. vivax genome. Reticulocyte-specific interactions with the 
PvRBPs (PvRBP1 and PvRBP2) were previously reported. Plasmodium falciparum reticulocyte-binding 
protein homologue 4 (PfRh4, a homologue of PvRBP1) was observed to possess erythrocyte-binding 
activity via complement receptor 1 on the erythrocyte surface. However, the reticulocyte-binding 
mechanisms of P. vivax are unclear because of the large molecular mass of PvRBP1 (>326 kDa) and the 
difficulty associated with in vitro cultivation. In the present study, 34 kDa of PvRBP1a (PlasmoDB ID: 
PVX_098585) and 32 kDa of PvRBP1b (PVX_098582) were selected from a 30 kDa fragment of PfRh4 for 
reticulocyte-specific binding activity analysis. Both PvRBP1a and PvRBP1b were found to be localized 
at the microneme in the mature schizont-stage parasites. Naturally acquired immune responses against 
PvRBP1a-34 and PvRBP1b-32 were observed lower than PvDBP-RII. The reticulocyte-specific binding 
activities of PvRBP1a-34 and PvRBP1b-32 were significantly higher than normocyte binding activity 
and were significantly reduced by chymotrypsin treatment. PvRBP1a and 1b, bind to reticulocytes and 
that this suggests that these ligands may have an important role in P. vivax merozoite invasion.
Plasmodium spp. cause public health problems worldwide, especially in tropical and subtropical nations. 
Plasmodium vivax has been reported to be the most widespread cause of malaria worldwide, with a harmful 
influence on an estimated 124–283 million people1. P. vivax is neglected compared to Plasmodium falciparum 
because it is associated with relatively low mortality; however, it is the most broadly and continuously spread 
species globally2,3.
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The investigation of specific interactions between parasite ligands and red blood cell (RBC) receptors is 
important to elucidate the complicated invasion mechanisms involved in multiple processes during the asex-
ual erythrocytic stage of the malaria parasite4. P. vivax preferentially interacts with reticulocytes (young RBCs) 
during the repetitive invasion process, whereas P. falciparum is able to invade all stages of RBCs in circulation. 
Specific interactions between the P. vivax ligand, Duffy binding protein (DBP) and RBC receptor Duffy antigen/
receptor for chemokines (DARC) were reported to be essential for invasion5,6. However, recently, Duffy-negative 
Malagasy clinical cases involving P. vivax infection have been reported, indicating that P. vivax may have an alter-
native invasion pathway7. One possible alternative pathway is mediated by the reticulocyte-binding protein (RBP) 
family. PvRBP1 and PvRBP2 were identified as essential parasite ligands from this family that selectively bind 
reticulocytes8,9. Whole-genome annotations of PvRBP1 (PvRBP1a, PvRBP1b and PvRBP1 partial-1) and PvRBP2 
(PvRBP2a, PvRBP2b, PvRBP2c, PvRBP2 partial-1, and PvRBP2 partial-2) have been completed and used to 
reveal promising vaccine candidates10,11. Analysis of the pvrbp1a and pvrbp1b (PVX_098585 and PVX_098582) 
amino acid sequence structures revealed that PvRBP1 contained two exons; the first exon encoded a signal pep-
tide, and the second exon encoded a hydrophobic sequence (transmembrane domain) at the C-terminal region 
and an arginyl-glycyl-aspartic acid (RGD) motif 8. PvRBP1a and PvRBP1b are highly transcribed during the par-
asite schizont stage10–12, suggesting that these proteins play important roles in reticulocyte invasion by blood stage 
parasites. However, the involved binding motif and whether the PvRBP proteins interact with reticulocytes have 
remained largely unknown. One study demonstrated robust invasion assay which has allowed testing molecules 
in invasion of 2C3 as the monoclonal antibody of DARC for blocked PvDBP interaction by short term P. vivax 
invasion process13. An invasion mechanism study of P. vivax faces a considerable hurdle owing to the inability to 
continuously culture the parasites in vitro14,15. To overcome these problems, we consider evidence from homolo-
gous protein families in other Plasmodium spp.
Reticulocyte binding-like (RBL) homologues have been found among human-, simian- and rodent-infecting 
Plasmodium spp.9,16,17. This highly consistent function from adhesive protein family members was based on the 
binding activity toward erythrocytes by P. falciparum and may provide clues that the PvRBP1s also play essen-
tial roles in parasite invasion through ligand-receptor interactions16,18,19. The erythrocyte-binding domain of 
reticulocyte-binding protein homologue 4 (PfRh4) from P. falciparum was identified as a homologous region to 
the PvRBP1 amino acid sequence. This domain showed erythrocyte-binding activity and was specifically inhib-
ited by antibodies16. PfRh4 interacted with the CCP1-3 site recognized by the complement receptor type 1 (CR1) 
on the erythrocyte surface via a sialic acid-independent invasion pathway. Several P. falciparum strains primarily 
use sialic acid-independent pathways for RBC invasion20–22. In PfRh5, erythrocyte-binding activity via basigin 
was demonstrated from the PfRh4-binding homologue site23,24. Recently, analysis of the PvRBP2a crystal struc-
ture showed structural conservation of the PfRh5 scaffold shape25,26. Interestingly, all PvRBP family members 
(PvRBP2a, PvRBP2b, PvRBP2c, PvRBP2 partial-1, PvRBP2 partial-2, PvRBP1a and PvRBP1b) share this protein 
structure at the N-terminal region; of these PvRBPs, PfRh4, PfRh5 and PvRBP2a showed erythrocyte-binding 
activities26. All PfRh family members (PfRh1, PfRh2a, PfRh2b, PfRh3, PfRh4, and PfRh5) with homologous 
domains revealed erythrocyte binding activities except PfRh3 (pseudogene)18,19,23,27. Overall, several studies 
have provided strong evidence for the involvement of this protein family in erythrocyte or reticulocyte binding. 
However, the characterization and identification of PvRBP1a and PvRBP1b are insufficient compared with other 
RBL family members.
In this study, we characterized PvRBP1a and PvRBP1b as PfRh4 erythrocyte-binding domain homologue 
regions. We demonstrated their exact subcellular localization in blood-stage parasites, their ability to acquire 
immune responses in malaria patients, and their binding activity with normocytes and reticulocytes under in 
vitro conditions.
Results
Schematic structures of PvRBP1a and PvRBP1b. The PvRBP1a and PvRBP1b gene sequences encode 
large-sized proteins (2,833 and 2,608 aa., respectively) with predicted high molecular weights (approximately 
326 and 303 kDa, respectively). PvRBP1a encodes a signal sequence (1–22 aa.) and transmembrane domain 
(2,756–2,774 aa.) and contains 16 cysteine residues. PvRBP1a-34 (351–599 aa.) is a putative functional domain 
homologue site of PvRBP1a and was defined based on the PfRh4-30 homologue site as an erythrocyte-binding 
domain. PvRBP1b also encodes a signal sequence (1–23 aa.) and contains 12 cysteine residues. PvRBP1b-32 
(339–587 aa.) is a predicted binding domain of PvRBP1b and was selected from the PvRBP1a-34 homologue 
region (Fig. 1a). The sequence alignment of PfRh4-30 with PvRBP1a-34 and PvRBP1b-32 generated using Clustal 
W and including the 600 aa. upstream of the N-terminal region showed that PfRh4-30 has 17.2% sequence iden-
tity with PvRBP1a-34, PfRh4-30 has 18.4% identity with PvRBP1b-32, and PvRBP1a-34 has 37.5% identity 
with PvRBP1b-32 (Fig. 1b). This putative binding sequence was predicted to represent the conserved domain in 
PvRBP1a (354–459 aa.) and PvRBP1b (342–450 aa.) that was present in the PfRh4-30 (330–440 aa.) 3D struc-
ture (Supplementary Fig. S1). These conserved structure domains also overlap the binding domain of the PfRh5 
(160–506 aa.) monoclonal antibody (PBD template c4u1gA) (Supplementary Fig. S1).
Expression and purification of recombinant PvRBP1a-34 and PvRBP1b-32. The recombinant 
PvRBP1a-34 and PvRBP1b-32 proteins were expressed in the wheat germ cell-free system and purified with a 
Ni-NTA affinity column (Qiagen, Hilden, Germany). The PvRBP1a-34 and PvRBP1b-32 fragments had expected 
molecular weights of approximately 34.4 kDa and 32.0 kDa, respectively, and were successfully expressed in their 
soluble forms (Fig. 2a). The recombinant protein purification was confirmed by western blotting with an anti-His 
antibody (Fig. 2b, Lane His). These recombinant proteins were used to immunize mice and rabbits to produce 
polyclonal antibodies. The immune sera raised against the recombinant proteins reacted with the PvRBP1a-34 
and PvRBP1b-32 proteins (Fig. 2b, Lane M and R). Similarly, mixed serum samples from 10 P. vivax-infected 
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patients specifically recognized recombinant PvRBP1a-34 and PvRBP1b-32. In contrast, neither pre-immune 
animal sera nor sera from healthy humans reacted with the recombinant antigens (Fig. 2b, Lane N). Immune 
sera raised against PvRBP1a-34 and PvRBP1b-32 specifically recognized their native antigens from P. vivax 
schizont-enriched lysates (Fig. 2c).
Humoral immune response against PvRBP1a-34 and PvRBP1b-32. The antigenicity of the 
PvRBP1a and PvRBP1b fragments was evaluated by protein array. For this experiment, serum samples were 
obtained from 104 vivax malaria patients and 72 healthy individuals in the Republic of Korea (ROK). The total 
IgG prevalences of PvRBP1a-34 and PvRBP1b-32 were 33.7% (mean fluorescence intensity; mean ± 2 standard 
deviation [S.D.], 3,593 ± 3,112) and 39.4% (mean ± 2 S.D.; 2,940 ± 2,296) sensitivity, respectively, with 95.8% 
specificity. Both proteins had high specificity, and significant differences were observed in the total IgG preva-
lence between the vivax patients and healthy individuals (p < 0.0001) (Table 1; Fig. 3a). PvDBP-RII was selected 
for the antigenicity analysis for comparison. For the antigenicity screening, sera from 72 vivax patients were ran-
domly chosen from the 104 samples. These data re-confirmed the high IgG prevalence against PvDBP-RII with 
56.9% sensitivity and 95.8% specificity (Table 1; Fig. 3a). There was no significant correlation between the para-
sitemia and the humoral immune response to PvRBP1a-34 (r2 = 0.0881, p = 0.373) and PvRBP1b-32 (r2 = 0.0747, 
p = 0.453) (Fig. 3b,c).
Subcellular localization of PvRBP1a and PvRBP1b. The subcellular localization of PvRBP1a and 
PvRBP1b in the merozoite parasites was observed using the anti-PvRBP1a-34 and anti–PvRBP1b-32 antibodies 
by confocal microscopic examination. Native PvRBP1a colocalized on the microneme of the merozoite together 
with the PvDBP microneme protein marker (Fig. 4a). The merozoite surface and rhoptry protein markers 
(PvMSP1 and PvRAMA, respectively) did not merge together (Fig. 4b,c). PvRBP1b also clearly colocalized with 
PvDBP (Fig. 4d) but not with PvRAMA or PvMSP1 (Fig. 4e,f).
Figure 1. Schematic structure and amino acid sequence alignments of PvRBP1a, PvRBP1b and PfRh4. 
(a) The PvRBP1a-34 (351–599 amino acid [aa.]) and PvRBP1b-32 (339–587 aa.) sequences homologous with 
PfRh4-30 (328–588 aa.) are represented in a yellow box. The signal peptide (black box), transmembrane domain 
(blue box), structure homologue (lined box), recombinant protein expression (black bar) and functional 
erythrocyte-binding domain (red bar) are indicated. (b) Clustal alignment of the PvRBP1a, PvRBP1b and 
PfRh4 homologous sequence domains. The red bar indicates the conserved identical amino acids in the 
alignment of the three proteins, the green bar indicates identical amino acids in two proteins, and the blue bar 
indicates diverse amino acids in the three proteins.
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Reticulocyte-binding activity of PvRBP1a-34 and PvRBP1b-32. The reticulocyte-binding activ-
ity evaluation of PvRBP1a-34 and PvRBP1b-32 was performed using a fluorescence-activated cell sorter 
(FACS)-based binding assay. The reticulocytes were enriched from cord blood, and a mean concentration of 
73.3% (95% confidence interval, 61.3–85.3%) was achieved (Fig. 5a). PvDBP-RII and the His-tagged GST pro-
tein were used as the positive and negative controls, respectively, for the binding activity evaluation. PvDBP-RII 
dramatically bound to reticulocytes at the 1 μ g/ml protein concentration and was saturated at the approxi-
mately 5 μ g/ml concentration (Fig. 5b). The PvRBP1a-34 and PvRBP1b-32 binding activities on reticulocytes 
were shown to increase in a concentration-dependent manner, and both proteins were saturated at the 20 μ g/ml 
concentration (Fig. 5b). PvDBP-RII has well-known binding activities with normocytes and reticulocytes via 
DARCs. PvDBP-RII binding was detected at the 20 μ g/ml concentration with a mean binding of 16.2% ± 5.2% 
with normocytes and 90.5% ± 9.0% with reticulocytes (p < 0.0002), which represented a 5.6-fold increase 
Figure 2. Recombinant PvRBP1a-34 and PvRBP1b-32 expression and western blotting of recombinant 
proteins and P. vivax schizont extracts with specific antibodies. (a) Recombinant protein expression 
and purification. The arrowhead indicates the specific bands for the purified PvRBP1a-34 (34.4 kDa) and 
PvRBP1b-32 (32.0 kDa) recombinant proteins. T, total translation mix; S, supernatant; P, pellet; Ft, flow-
through; E, elution. (b) The purified recombinant PvRBP1a-34 and PvRBP1b-32 proteins were probed with the 
anti-penta-His antibody (His), immune mouse sera (M), immune rabbit sera (R) and preimmune rabbit sera 
(N) under reducing conditions as well as pooled patient sera from 10 vivax malaria patients (P) and pooled 
sera from 10 healthy people (H). (c) Recognition of the native PvRBP1a and PvRBP1b antigens in the P. vivax 
schizont parasite lysate with rabbit antisera raised against the recombinant PvRBP1a-34 and PvRBP1b-32 
proteins under reducing conditions. (1) Native PvRBP1a with rabbit immune sera; (3) native PvRBP1b with 
rabbit immune sera; (2) and (4) represent normal RBC extracts with PvRBP1a and PvRBP1b rabbit immune 
sera, respectively. The arrowhead represents the target bands and their processed fragments.
Antigen
No. of patient samples
95% CIb MFIc
No. of healthy samples
95% CI MFI p valueePositive Negative Total (%)a Positive Negative Total (%)d
PvDBP-RII 41 31 72 (56.9) 45.4–67.7 5968.4 1 23 24 (95.8) 79.8–99.3 2769.5 p < 0.0001
PvRBP1a-34 35 69 104 (33.7) 25.3–43.2 5513.7 3 69 72 (95.8) 88.5–98.6 3593.4 p < 0.0001
PvRBP1b-32 41 63 104 (39.4) 30.6–49.0 5452.2 3 69 72 (95.8) 88.5–98.6 2939.6 p < 0.0001
Table 1.  Prevalence, 95% confidence intervals, and mean fluorescence intensity of IgG responses to 
each fragment of P. vivax DBP-RII, RBP1a-34 and RBP1b-32 in human patients and healthy individual 
serum samples. aSensitivity: percentage of positive in patient samples. bCI: confidence interval. cMFI: mean 
fluorescence intensity. dSpecificity: percentage of negative in healthy samples. eDifferences in the total IgG 
prevalence for each antigen between vivax patients and healthy individuals were calculated with Student’s t-test. 
A p value of < 0.05 is considered statistically significant.
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in the reticulocytes (Fig. 5c). The PvRBP1a-34 and PvRBP1b-32 proteins specifically bound to reticulocytes 
(16.2% ± 6.4% and 53.1% ± 14.0%, respectively) and were significantly higher reticulocyte binding activity than 
normocyte-binding activity (p < 0.0178 and p < 0.0032, respectively) (Fig. 5c). The normocyte-binding activity 
of the two PvRBP1 proteins was similar to that of GST-His and was below the cut-off percentage that indicated no 
binding activity with normocytes. The GST-His protein was included as the negative control and was used as the 
binding cut-off value for the normocyte-binding activity analysis. The GST control was shown to have very low 
binding activity in the normocyte and reticulocyte populations, respectively.
The specificity of the reticulocyte-binding activity was confirmed by the binding inhibition assay. The anti-
bodies against PvDBP-RII, PvRBP1a-34 and PvRBP1b-32 were able to inhibit the binding of each protein in a 
concentration-dependent manner (Fig. 6a). The recombinant proteins bound to reticulocytes treated with neu-
raminidase, trypsin or chymotrypsin. The relative binding activity of the chymotrypsin-treated reticulocytes with 
PvDBP-RII was inhibited by more than half compared to PvDBP-RII (percentage of relative binding, mean + SD: 
47.5% + 17.1%); this binding activity was significantly different (p = 0.004) than the binding activity for normal 
reticulocytes. Similarly, PvRBP1a-34 (35.9% + 5.6%) was significantly inhibited by chymotrypsin (p = 0.033). The 
binding activity of PvRBP1b-32 was significantly inhibited by trypsin (55.4% + 13.3%, p = 0.033) and chymot-
rypsin (46.7% + 18.9%, p = 0.029), similar to the PfRh4-30 erythrocyte-binding domain (Fig. 6b).
Discussion
P. vivax invades host red blood cells via complex mechanisms, such as the recognition and interaction of retic-
ulocytes with merozoites in the blood stream. The most suitable invasion mechanism candidates were PvRBP1 
and PvRBP2 in a previous report8. These proteins demonstrated concentration-dependent reticulocyte-binding 
activity and accordingly demonstrated a preference for interactions with reticulocytes rather than normo-
cytes. PvRBP homologues have been found in various human (P. vivax and P. falciparum), simian (P. cynomo-
lgi and P. knowlesi) and rodent (P. berghei and P. yoelii) malarial agents. The first member of this RBL family 
was identified in a rodent malarial agent (P. yoelii), and its function was identified as reticulocyte invasion28. 
The Rhoptry protein with a 235 kDa molecular weight (PY235) identified in P. yoelii was involved in host cell 
selection for invasion29,30. Subsequently, multigene family paralogs were identified in P. vivax, including PvRBP1 
and PvRBP29. The complete genome of the P. vivax Sal-I strain was sequenced, and three pvrbp1 genes were 
found: PvRBP1a (PVX_098585), PvRBP1b (PVX_098582) and PvRBP1 partial (PVX_125738)11. P. falciparum 
reticulocyte-binding protein homologues (PfRh family; PfRh1, PfRh2a, PfRh2b, PfRh4, and PfRh5) were also 
detected in PvRBPs17,31–34 and showed erythrocyte-binding activity. PfRh4 contained an erythrocyte-binding 
domain that was homologous to the PvRBP1 site16,21,22,35. The PvRBP1 homologous domain was demonstrated 
to exhibit erythrocyte-binding activity in the 30 kDa PfRh4 ecto-domain16. Previously, full-length PvRBP1 was 
Figure 3. Antigenicity and correlation of parasitemia with PvRBP1a-34 and PvRBP1b-32. (a) Total IgG 
prevalence of each domain with the vivax malaria patient sera and healthy individual samples. The bar indicates 
the mean ± standard deviation of the mean fluorescence intensity (MFI). The p values were calculated using 
Student’s t-test. (b) The correlation between PvRBP1a-34 and (c) PvRBP1b-32 with parasitemia was evaluated 
using Spearman’s correlation test. An MFI > 10,000 was considered high intensity and > 0.2 was considered high 
parasitemia.
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shown to exhibit reticulocyte-binding activity; however, the exact binding domain and its receptor on the retic-
ulocyte surface are still unknown8. In this study, the binding domains of the PvRBP1a and PvRBP1b from PfRh4 
binding domain homologue16 were confirmed and shown to possess reticulocyte-binding activity via binding 
domains that were not characterized in the previous study8. Although the sequence similarity to the PvRBP1a- 
and PfRh4-binding domains was relatively low (33.4%), the characterization of this homologous domain is 
important to clarify the erythrocyte binding activity of the PvRBP1 protein.
Figure 4. Localization of PvRBP1a and PvRBP1b. (a–f) Subcellular localization of the PvRBP1a and 
PvRBP1b proteins in asexual blood-stage P. vivax parasites. PvRBP1a or PvRBP1b rabbit immune sera (red 
color) were dual labeled with mouse immune sera against PvMSP1-19 (merozoite surface), PvRAMA (rhoptry) 
and PvDBP-RII (microneme) (green). The nuclei are visualized with DAPI (blue).
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A previous study reported that native PvRBP1 was localized at the apical pole of the merozoite8. This study 
revealed the localization of PvRBP1a and PvRBP1b, which were expressed at the microneme similar to the P. 
knowlesi reticulocyte-binding proteins (PKH_146970 and PKH146980)36 but differed from other RBL family 
members, such as PfRh and PY235, which localized in the rhoptry16. Our findings suggest that PvRBP1 may have 
functional activity similar to that of the microneme protein PvDBP, which plays a role in junction formation dur-
ing merozoite invasion of host cells. Another possibility is that PvRBP1 may participate in the cascade of events 
involved in invasion through specific interactions with a receptor on the reticulocyte surface during the release 
of microneme proteins.
The fragment representing PvRBP1 (435–777 aa.) contains the most polymorphic region of the protein, sug-
gesting that it may be a target of functional antibodies37–39. In the present study, the PfRh4 homologue fragments 
PvRBP1a-34 (352–599 aa.) and PvRBP1b-32 (340–587 aa.) partially overlapped the PvRBP1 polymorphic region. 
PvRBP1a-34 and PvRBP1b-32 were observed to have low antigenicity with the vivax patient serum samples. 
Our results also confirmed the results from our previous study and another report39–41. PvRBP1b had relatively 
low antigenicity among the PvRBP family proteins compared with the high antigenicity of PvRBP2c40,41. The 
PvDBP-RII domain contains polymorphic sequences that may affect antibody recognition for protection against 
parasite invasion42,43. These results are consistent with the finding that Plasmodium polymorphic proteins are 
poorly immunogenic or elicit antibody responses that are short lived in the absence of frequent natural infec-
tions38. PvDBP-RII domain was also shown polymorphic sequences that may affect to antibodies recognition 
for the protection of parasite invasion because of the immune pressure42,43. Highly polymorphic domains of 
PvRBP1a and PvRBP1b may also possible to affect human antibodies recognition and not much effective for 
the protection of invasion similar properties as PvDBP-RII39. The study of anti-PvRBP1 and anti-PvDBP-RII 
Figure 5. Reticulocyte-binding activity of recombinant PvRBP1a-34 and PvRBP1b-32 in the FACS-based 
assay. (a) Dot plot indicates the unstained RBCs as the gating control (upper left), the enriched reticulocytes 
(thiazole orange, TO+) (upper center) and the binding control containing no protein (phosphate-buffered 
line, PBS) in the added fractions (upper right). Recombinant proteins (20 μ g/ml) added to the test group are 
shown in the lower image. (b) Reticulocyte-binding saturation assay showing the total binding percentage 
of reticulocytes with serial concentrations of the proteins. The PvDBP-RII and GST-His proteins were used 
as positive and negative controls, respectively. Data are shown as the mean ± standard deviation (S.D.) of at 
least three independent experiments. (c) Comparison between TO+ and TO− (reticulocytes and normocytes, 
respectively) binding activity with 20 μ g/ml of each protein. Data are shown as the mean ± S.D. of at least three 
independent experiments.
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antibodies seroprevalence in Brazil revealed predominantly cytophilic IgGs and significantly correlated with a 
number of past vivax malaria episodes, suggested that anti-PvRBP1 antibodies may have a long duration in repeat 
exposures38,39.
The most promising function of the PvRBPs is their reticulocyte-binding and selection activity8. In this study, 
fragments of a high-likelihood binding functional domain from PfRh4 were selected for the FACS-based bind-
ing assay with reticulocytes enriched by more than 70%. The PvRBP1a-34 and PvRBP1b-32 fragments exhib-
ited specific binding activity with reticulocytes but not erythrocytes. A recent study of the PvRBP2a (160–460 
aa.) fragment showed binding activities with both erythrocytes and reticulocytes26. These fragment structures 
shared the PfRh5 scaffold shape. These strong binding activities suggest that the PvRBP1a and PvRBP1b ligands 
have reticulocyte-selective activities that are dependent on an interaction with a specific, abundantly expressed 
reticulocyte receptor. PvDBP-RII showed stronger binding activity in reticulocytes than in erythrocytes. DARCs 
were more abundantly expressed on the reticulocytes and had an increased capacity to bind with specific recep-
tors44. Although the identity of the PvRBP1a and PvRBP1b receptors is unclear, the present study clearly showed 
neuraminidase resistance in both proteins. These results suggest that PvRBP1a and PvRBP1b interact with a 
non-sialic acid receptor on the reticulocytes. PvRBP1b-32 showed both trypsin and chymotrypsin sensitivity, 
similar to PfRh416. The enzyme-treated reticulocyte-binding assay showed significant inhibition of the binding 
activity in the presence of chymotrypsin; however, the binding activity was reduced by approximately 50% com-
pared with the untreated samples. One possible explanation is that the abundant expression of the reticulocyte 
receptor overcame the enzyme reaction capacity. For example, the PvDBP-RII positive control also showed some 
binding following chymotrypsin treatment of the reticulocytes.
In conclusion, we proposed that PvRBP1a and PvRBP1b might play roles in specific reticulocyte binding 
through direct interactions between the recombinant proteins and the reticulocytes enriched from cord blood. 
These interactions contributed to the inhibition of immune serum samples, the binding specificity following 
Figure 6. Specificities of PvRBP1a- and PvRBP1b-binding and reticulocyte receptors. (a) Antibody 
inhibition assay. Serial dilutions of mouse sera raised to inhibit the protein-binding activity. Data are shown as 
the mean ± S.D. of at least three independent experiments. (b) A flow cytometry-based RBC-binding assay was 
performed with untreated RBCs (Un) and neuraminidase- (Nm), trypsin- (T), and chymotrypsin (Ct)-treated 
RBCs. Significant differences are shown as single asterisks, p < 0.05; and double asterisks, p < 0.01. Data are 
shown as the mean ± S.D. of at least three independent experiments.
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enzyme treatment of the reticulocytes, the induction of relatively low IgG antibody responses in patients, and the 
localization of the proteins on the microneme of the apical organelles in schizont-stage parasites. Understanding 
the reticulocyte-binding antigen profile is important for elucidating the P. vivax invasion mechanisms. Future 
studies will determine the critical binding motifs of the PvRBP1a and PvRBP1b small molecules and evaluate the 
interaction receptor expressed on the reticulocytes during P. vivax invasion.
Materials and Methods
Human serum, parasite and cord blood samples. P. vivax patient samples were confirmed by micro-
scopic examination (mean parasitemia, 0.12%). All samples were collected from the local hospital in Gangwon 
Province in malaria-endemic areas of the Republic of Korea (ROK) from 2008 to 2011. Healthy individual sera 
were collected from non-endemic areas. We used serum samples from 104 vivax patients and 72 healthy people 
for the humoral immune response analysis by protein array. Cord blood was collected in a 10 ml sodium heparin 
tube (BD Vacutainer®, Becton-Dickinson Co., NJ USA). All experiments were performed in accordance with 
relevant guidelines and regulations and all experimental protocols involving human samples approved by the 
Kangwon National University Hospital Ethical committee (IRB No. 2014-08-008-002). The written informed 
consent was obtained from all subjects.
Expression and purification of the recombinant PvRBP1a-34 and PvRBP1b-32 proteins. 
Genomic DNA was extracted from a whole-blood sample from a parasite-infected patient. DNA was extracted 
from 200 μ l of patient whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) fol-
lowing the manufacturer’s protocol and was used for amplification and subsequence cloning of the PvRBP1a 
and PvRBP1b genes. The primer sets were designed based on the P. vivax Sal-1 strain pvrbp1a (PlasmoDB ID: 
PVX_098585) and pvrbp1b (PVX_098582) sequences and contained a region homologous to the PfRh4-binding 
domain (PvRBP1a-34 and PvRBP1b-32): PvRBP1a forward 5′ -AACGAACTAGGTATAGACATT-3′ 
and reverse 5′ -ATTCAAACTCTATCTTCAGTTC-3′ (34 kDa fragment) and PvRBP1b forward 5′ - 
GAAAGGGAGAATATAGACATTGCAG-3′ and reverse 5′ -AATTCCCATGCACATTTTTCAA-3′ (32 kDa 
fragment). Each amplicon fragment was inserted into the pEU-E01-His-TEV-MCS vector (Cell Free Sciences, 
Matsuyama, Japan) containing a hexa-His tag at the N-terminus. Plasmid DNA fragments encoding PvRBP1a-34 
(aa. position 352 to 599) and PvRBP1b-32 (aa. position 340 to 587) were generated and confirmed by sequencing 
analysis. These recombinant proteins were expressed using the wheat-germ cell-free expression system (Cell Free 
Sciences, Matsuyama, Japan) and purified using a Ni-affinity column (Qiagen) with an elution buffer containing 
500 mM imidazole as previously described45,46. The PvDBP region II (RII) protein was expressed by E. coli and 
purified as previously described47. GST-His (glutathione S-transferase 6× His tag) protein expression was per-
formed following the manufacturer’s protocol (GST Gene Fusion System, GE Healthcare Life Sciences, Uppsala, 
Sweden).
Animal immune sera production. Female BALB/c mice (6 weeks old; Daehan Biolink Co., Eumsung, 
ROK) were used for the production of polyclonal antibodies against the recombinant PvRBP1a-34, PvRBP1b-32 
and PvDBP-RII proteins. Groups of three mice were injected intraperitoneally with 20 μ g of recombinant pro-
tein with Freund’s complete adjuvant (Sigma-Aldrich, St. Louis, MO, USA). Booster injections were given 
3 and 5 weeks after the initial injection using the same amount of antigen with Freund’s incomplete adjuvant 
(Sigma-Aldrich), and mouse sera were collected 2 weeks after the final boost. To generate antibodies against 
PvRBP1a-34, PvRBP1b-32 and PvDBP-RII from rabbits, Japanese white rabbits were immunized subcutaneously 
with 250 μ g of purified proteins with Freund’s complete adjuvant, followed by 250 μ g with Freund’s incomplete 
adjuvant thereafter. All immunizations were administered three times at three-week intervals. The antisera were 
collected two weeks after the final boost. All animal experimental protocols were approved by the Institutional 
Animal Care and Use Committee of Kangwon National University, and the experiments were conducted accord-
ing to the Ethical Guidelines for Animal Experiments of Kangwon National University (KIACUC-13-0001).
SDS-PAGE and western blot analysis. Each recombinant protein (1 μ g/well) was prepared in 2× reduc-
ing sample buffer, separated by 12% SDS-PAGE and then stained with Coomassie brilliant blue. For the western 
blot analysis, the proteins were transferred to PVDF membranes (Millipore, Bedford, MA, USA) by electro-
phoresis and incubated with blocking buffer (PBS containing 0.2% Tween 20 and 5% skim milk, PBS-T) over-
night at 4 °C. The PVDF membrane containing recombinant proteins was incubated for 1.5 h at 37 °C with an 
anti-penta-His mouse antibody (1:2,000) (Qiagen) and animal immune serum (1:1,000) against each recombi-
nant protein. After washing, the membrane was incubated with the goat anti-rabbit IRDye® 680 (1:5,000) and 
goat anti-mouse IRDye® 800 (1:10,000) antibodies (LI-COR Bioscience, Lincoln, NE, USA) in PBS-T for 1 h at 
37 °C. To determine the reactivity of patient sera with the recombinant proteins, the recombinant proteins were 
probed with pooled sera from 10 patients at a 1:100 dilution in PBS-T and incubated with the goat anti-human 
IRDye®680 (1:10,000) antibody. Data were measured using the Odyssey infrared imaging system (LI-COR 
Bioscience) and analyzed with the Odyssey software (LI-COR Bioscience).
Protein array. Three aminopropyl-coated slides were prepared as described previously48. Briefly, the 
slides were spotted and then each recombinant protein was applied to the spot at concentrations of 50 ng/μ l for 
PvRBP1a-34 and 100 ng/μ l for PvRBP1b-32. The slides were incubated for 2 h at 37 °C. After blocking, each spot 
was probed with 1 μ l of patient or healthy serum (1:25 dilution in PBS-T) followed by incubation for 1 h at 37 °C. 
The arrays were visualized with 10 ng/μ l of Alexa Fluor 546 goat anti-human IgG (Invitrogen, Carlsbad, CA, USA) 
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in PBS-T for 1 h at 37 °C and scanned with a ScanArray Gx laser confocal scanner (PerkinElmer, Norwalk, CT, 
USA). The positive cut-off values of the negative control plus two standard deviations were used.
Indirect immunofluorescence assay (IFA). Mature schizont-stage parasites were purified from 
whole-blood samples from vivax malaria patients. The parasite antigen slides were prepared with ice-cold ace-
tone for fixation and blocked with PBS containing 5% skim milk at 37 °C for 30 min. The following primary 
antibodies were used: rabbit anti-PvRBP1a-34 (1:50) and anti-PvRBP1b-32 (1:50) with anti-PvRAMA (1:200), 
anti-PvDBP-RII (1:100) and anti-PvMSP1-19 (1:200). The following secondary antibodies were used: Alexa 
546-conjugated goat anti-mouse IgG or Alexa 488-conjugated goat anti-rabbit IgG (Invitrogen) at a 1:500 dilu-
tion. DAPI (4′ ,6′ -diamidino-2-phenylindole, Invitrogen) was applied at a 1:1,000 dilution at 37 °C for 30 min to 
stain the nuclei. The slides were mounted with ProLong Gold antifade reagent (Invitrogen) and visualized under 
oil immersion using a Flowview® FV1000 Laser Scanning Confocal imaging System (Olympus, Tokyo, Japan) 
equipped with a 60× oil objective. Images were captured using the FV10-ASW 3.0 viewer software and prepared 
for publication with Adobe Photoshop CS5 (Adobe Systems, San Jose, CA, USA). Each fluorescence graphic con-
tained more than 500 pixels calculated by Image J (NIH, USA).
Reticulocyte enrichment from cord blood. Reticulocytes were enriched from heparinized umbilical 
cord blood with a 19% Nycodenz solution (Axis-Shield, Oslo, Norway) in high-KCl buffer using gradient centrif-
ugation49. Fresh cord blood was washed twice with incomplete RPMI 1640 medium, and white blood cells were 
removed using an NWF filter (Zhixing Bio Co. LTD., Bengbu, China). After centrifugation, packed cells were 
resuspended with a high-KCl buffer (pH 7.4) and then incubated at 4 °C for 3 h with rotation on a shaking rocker. 
Nycodenz solution (19%, 3 ml) was transferred into 15 ml tubes. Then, 5 ml of the RBC-high KCl buffer mixture 
was added on top of the Nycodenz solution layer and centrifuged at 3,000× g for 30 min without braking. The 
reticulocytes in the interface layer were harvested and washed three times with RPMI 1640 medium. The reticulo-
cyte purity was calculated from thin blood smear samples with new methylene blue stain under light microscopy 
and thiazole orange (TO) staining of the enriched reticulocytes. A total of 200,000 events were acquired per sam-
ple using the FACS Accuri™ C6 Flow Cytometer (Becton-Dickinson Co., Mansfield, MA, USA).
Enzyme treatment of RBCs. Reticulocyte-enriched samples were prepared with up to 50% hematocrit. 
The RBCs were washed with 500 μ l of incomplete RPMI 1640 medium twice by centrifugation at 500× g for 
3 min at 4 °C. The RBCs were incubated with neuraminidase (from Vibrio cholera, Sigma-Aldrich), trypsin (from 
bovine pancreas, Sigma-Aldrich) and chymotrypsin (from bovine pancreas, Sigma-Aldrich) at 37 °C on a rotator 
for 1 h. The trypsin and chymotrypsin-treated RBCs were incubated with a trypsin inhibitor (from the Glycine 
max soybean, Sigma) at 37 °C for 10 min. The RBC samples were washed twice with 10 ml of incomplete RPMI 
1640 medium. The packed cells were prepared at a concentration of 1 × 106 cell/ml and used for flow cytometry 
analysis.
Reticulocyte-binding assay by flow cytometry. The reticulocyte-enriched samples were used for the 
flow cytometry-based direct-binding assay. Briefly, 1 × 106 reticulocytes/ml or the same concentration of reticu-
locytes treated with each enzyme was incubated for 4 h at 25 °C with 0 to 20 μ g of hexa-His-tagged recombinant 
PvRBP1a-34 or PvRBP1b-32 protein. PvDBP-RII and GST-His were used as the positive and negative controls 
for the reticulocyte binding assay, respectively. The samples were washed twice with 200 μ l of PBS containing 
1% BSA (PBS-BSA) and incubated with a mouse anti-penta-His Alexa Fluor 647-conjugated monoclonal anti-
body (Qiagen) for 1 h at 4 °C in the dark. The samples were washed three times with PBS-BSA and incubated 
with the Thiazole Orange (TO) Retic-COUNT reagent (Becton-Dickinson Co., San Jose, CA, USA) for 30 min 
at 25 °C. For the fluorescent detection of each RBC, a total of 100,000 events were acquired per sample using the 
FACS Accuri™ C6 Flow Cytometer (BD). The flow cytometric results were analyzed using FlowJo 7.6 (Treestar, 
Ashland, OR, USA). Unstained cells and cells singly stained with TO were used to separate the normocytes and 
reticulocytes, respectively.
Statistical analysis. The data were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA, 
USA), SigmaPlot (Systat Software Inc., San Jose, CA, USA), and Microsoft Excel 2013 (Microsoft, Redmond, WA, 
USA). Two-dimensional scatter data were obtained as a simple scatter with a regression graph of x, y axis pairs50. 
For the protein array, Student’s t-test was used to compare the experimentally measured values of each group. 
Differences of p < 0.05 were considered significant.
References
1. World Health Organization. World malaria report (2014).
2. Mueller, I. et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9, 555–566, 
doi: 10.1016/S1473-3099(09)70177-X (2009).
3. Mendis, K., Sina, B. J., Marchesini, P. & Carter, R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64, 
97–106 (2001).
4. Cowman, A. F. & Crabb, B. S. Invasion of red blood cells by malaria parasites. Cell 124, 755–766, doi: 10.1016/j.cell.2006.02.006 
(2006).
5. Michon, P., Fraser, T. & Adams, J. H. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the 
Plasmodium vivax Duffy binding protein. Infect Immun 68, 3164–3171 (2000).
6. Chitnis, C. E. & Sharma, A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 24, 29–34, doi: 10.1016/j.
pt.2007.10.004 (2008).
7. Menard, D. et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci 
USA 107, 5967–5971, doi: 10.1073/pnas.0912496107 (2010).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:26993 | DOI: 10.1038/srep26993
8. Galinski, M. R., Medina, C. C., Ingravallo, P. & Barnwell, J. W. A reticulocyte-binding protein complex of Plasmodium vivax 
merozoites. Cell 69, 1213–1226 (1992).
9. Galinski, M. R., Xu, M. & Barnwell, J. W. Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) shares structural features with 
PvRBP-1 and the Plasmodium yoelii 235 kDa rhoptry protein family. Mol Biochem Parasitol 108, 257–262 (2000).
10. Li, J. & Han, E. T. Dissection of the Plasmodium vivax reticulocyte binding-like proteins (PvRBPs). Biochem Biophys Res Commun 
426, 1–6, doi: 10.1016/j.bbrc.2012.08.055 (2012).
11. Carlton, J. M. et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455, 757–763, doi: 
10.1038/nature07327 (2008).
12. Bozdech, Z. et al. The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria 
parasites. Proc Natl Acad Sci USA 105, 16290–16295, doi: 10.1073/pnas.0807404105 (2008).
13. Russell, B. et al. A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood 118, e74–81, doi: 10.1182/
blood-2011-04-348748 (2011).
14. Noulin, F., Borlon, C., Van Den Abbeele, J., D’Alessandro, U. & Erhart, A. 1912–2012: a century of research on Plasmodium vivax in 
vitro culture. Trends Parasitol 29, 286–294, doi: 10.1016/j.pt.2013.03.012 (2013).
15. Roobsoong, W. et al. Improvement of culture conditions for long-term in vitro culture of Plasmodium vivax. Malar J 14, 297, doi: 
10.1186/s12936-015-0815-z (2015).
16. Gaur, D., Singh, S., Jiang, L., Diouf, A. & Miller, L. H. Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds 
to erythrocytes and blocks invasion. Proc Natl Acad Sci USA 104, 17789–17794, doi: 10.1073/pnas.0708772104 (2007).
17. Rayner, J. C., Galinski, M. R., Ingravallo, P. & Barnwell, J. W. Two Plasmodium falciparum genes express merozoite proteins that are 
related to Plasmodium vivax and Plasmodium yoelii adhesive proteins involved in host cell selection and invasion. Proc Natl Acad 
Sci USA 97, 9648–9653, doi: 10.1073/pnas.160469097 (2000).
18. Gao, X. et al. Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites. PLoS Pathog 
4, e1000104, doi: 10.1371/journal.ppat.1000104 (2008).
19. Sahar, T. et al. Plasmodium falciparum reticulocyte binding-like homologue protein 2 (PfRH2) is a key adhesive molecule involved 
in erythrocyte invasion. PLOS ONE 6, e17102, doi: 10.1371/journal.pone.0017102 (2011).
20. Tham, W. H. et al. Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium falciparum into 
human erythrocytes. Infect Immun 77, 2427–2435, doi: 10.1128/IAI.00048-09 (2009).
21. Park, H. J. et al. Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein 
PfRh4 on the human immune adherence receptor. J Biol Chem 289, 450–463, doi: 10.1074/jbc.M113.520346 (2014).
22. Tham, W. H. et al. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Proc 
Natl Acad Sci USA 107, 17327–17332, doi: 10.1073/pnas.1008151107 (2010).
23. Rodriguez, M., Lustigman, S., Montero, E., Oksov, Y. & Lobo, C. A. PfRH5: a novel reticulocyte-binding family homolog of 
plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLOS ONE 3, e3300, doi: 10.1371/journal.
pone.0003300 (2008).
24. Crosnier, C. et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534–537, doi: 
10.1038/nature10606 (2011).
25. Chen, L. et al. Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. Elife 3, doi: 10.7554/
eLife.04187 (2014).
26. Gruszczyk, J. et al. Structurally conserved erythrocyte-binding domain in Plasmodium provides a versatile scaffold for alternate 
receptor engagement. Proc Natl Acad Sci USA 113, E191–200, doi: 10.1073/pnas.1516512113 (2016).
27. Taylor, H. M. et al. Plasmodium falciparum homologue of the genes for Plasmodium vivax and Plasmodium yoelii adhesive proteins, 
which is transcribed but not translated. Infect Immun 69, 3635–3645, doi: 10.1128/IAI.69.6.3635-3645.2001 (2001).
28. Khan, S. M., Jarra, W., Bayele, H. & Preiser, P. R. Distribution and characterisation of the 235 kDa rhoptry multigene family within 
the genomes of virulent and avirulent lines of Plasmodium yoelii. Mol Biochem Parasitol 114, 197–208 (2001).
29. Khan, S. M., Jarra, W. & Preiser, P. R. The 235 kDa rhoptry protein of Plasmodium (yoelii) yoelii: function at the junction. Mol 
Biochem Parasitol 117, 1–10 (2001).
30. Keen, J., Holder, A., Playfair, J., Lockyer, M. & Lewis, A. Identification of the gene for a Plasmodium yoelii rhoptry protein. Multiple 
copies in the parasite genome. Mol Biochem Parasitol 42, 241–246 (1990).
31. Hayton, K. et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium 
falciparum invasion. Cell Host Microbe 4, 40–51, doi: 10.1016/j.chom.2008.06.001 (2008).
32. Kaneko, O., Mu, J., Tsuboi, T., Su, X. & Torii, M. Gene structure and expression of a Plasmodium falciparum 220-kDa protein 
homologous to the Plasmodium vivax reticulocyte binding proteins. Mol Biochem Parasitol 121, 275–278 (2002).
33. Rayner, J. C., Vargas-Serrato, E., Huber, C. S., Galinski, M. R. & Barnwell, J. W. A Plasmodium falciparum homologue of Plasmodium 
vivax reticulocyte binding protein (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway. J Exp Med 194, 1571–1581 
(2001).
34. Triglia, T. et al. Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins in 
Plasmodium vivax. Infect Immun 69, 1084–1092, doi: 10.1128/IAI.69.2.1084-1092.2001 (2001).
35. Reiling, L. et al. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human 
antibodies against malaria. PLOS ONE 7, e45253, doi: 10.1371/journal.pone.0045253 (2012).
36. Meyer, E. V. et al. The reticulocyte binding-like proteins of P. knowlesi locate to the micronemes of merozoites and define two new 
members of this invasion ligand family. Mol Biochem Parasitol 165, 111–121, doi: 10.1016/j.molbiopara.2009.01.012 (2009).
37. Rojas Caraballo, J., Delgado, G., Rodriguez, R. & Patarroyo, M. A. The antigenicity of a Plasmodium vivax reticulocyte binding 
protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys. Vaccine 
25, 3713–3721, doi: 10.1016/j.vaccine.2006.12.041 (2007).
38. Ferreira, A. R. et al. Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of 
Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1* /DQB1* in malaria exposed individuals 
from the Brazilian Amazon. PLOS ONE 9, e105828, doi: 10.1371/journal.pone.0105828 (2014).
39. Tran, T. M. et al. Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon 
population. Am J Trop Med Hyg 73, 244–255 (2005).
40. Hietanen, J. et al. Gene models, expression repertoire and immune response of Plasmodium vivax Reticulocyte Binding Proteins. 
Infect Immun, doi: 10.1128/IAI.01117-15 (2015).
41. Han, J. H. et al. Identification of Immunodominant B-cell Epitope Regions of Reticulocyte Binding Proteins in Plasmodium vivax 
by Protein Microarray Based Immunoscreening. Korean J Parasitol 53, 403–411, doi: 10.3347/kjp.2015.53.4.403 (2015).
42. Cole-Tobian, J. & King, C. L. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol 
127, 121–132 (2003).
43. Chootong, P. et al. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. 
Infect Immun 78, 1089–1095, doi: 10.1128/IAI.01036-09 (2010).
44. Liu, J., Guo, X., Mohandas, N., Chasis, J. A. & An, X. Membrane remodeling during reticulocyte maturation. Blood 115, 2021–2027, 
doi: 10.1182/blood-2009-08-241182 (2010).
45. Chen, J. H. et al. Measurement of naturally acquired humoral immune responses against the C-terminal region of the Plasmodium 
vivax MSP1 protein using protein arrays. Parasitol Res 109, 1259–1266, doi: 10.1007/s00436-011-2370-z (2011).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:26993 | DOI: 10.1038/srep26993
46. Arumugam, T. U. et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage 
vaccine candidate antigen. Infect Immun 79, 4523–4532, doi: 10.1128/IAI.05412-11 (2011).
47. Singh, S. et al. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding 
domain of Plasmodium vivax duffy-binding protein. J Biol Chem 276, 17111–17116, doi: 10.1074/jbc.M101531200 (2001).
48. Chen, J. H. et al. Immunoproteomics profiling of blood stage Plasmodium vivax infection by high-throughput screening assays. J 
Proteome Res 9, 6479–6489, doi: 10.1021/pr100705g (2010).
49. Sorette, M. P., Shiffer, K. & Clark, M. R. Improved isolation of normal human reticulocytes via exploitation of chloride-dependent 
potassium transport. Blood 80, 249–254 (1992).
50. Hans, N. et al. Identification and characterization of a novel Plasmodium falciparum adhesin involved in erythrocyte invasion. PLOS 
ONE 8, e74790, doi: 10.1371/journal.pone.0074790 (2013).
Acknowledgements
This work was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health and 
Welfare, Republic of Korea (A121180), by the National Research Foundation of Korea (NRF) grant funded by 
the Korea government (MSIP) (NRF-2014R1A2A1A11052079), and by Basic Science Research Program through 
the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning 
(2015R1A4A1038666). The funders had no role in study design, data collection and analysis, decision to publish, 
or preparation of the manuscript.
Author Contributions
J.-H.H. and E.-T.H. conceived of and designed the study. J.-H.H., S.-K.L., F.M., K.S.H., S.-H.H., W.S.P. and J.S. 
performed parasite sample collection, cell experiments, animal experiments and flow cytometry experiments. 
J.-H.H. and F.M. purified reticulocytes from cord blood samples. T.T. and M.H.N. expressed recombinant 
proteins. S.N. collected the cord blood samples. J.-H.H. performed the statistical analysis of the clinical samples 
and wrote the manuscript draft. E.-T.H. finalized the manuscript. All authors read and approved of the final 
manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Han, J.-H. et al. Identification of a reticulocyte-specific binding domain of Plasmodium 
vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain. Sci. Rep. 6, 
26993; doi: 10.1038/srep26993 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
